Considering the above-mentioned recent data from the ADAURA trial, osimertinib has been reported to achieve a 5-year overall survival rate of 85% for patients with stage II to IIIA resected NSCLC harbouring EGFR mutations against the 73% achieved by placebo. Here, EGFR is linked to non-small cell lung carcinoma.